| Q55379563 | Anti-Depressant Fluoxetine Reveals its Therapeutic Effect Via Astrocytes. |
| Q39717209 | Antidepressant fluoxetine suppresses neuronal growth from both vertebrate and invertebrate neurons and perturbs synapse formation between Lymnaea neurons |
| Q91843016 | Antidepressants are modifiers of lipid bilayer properties |
| Q48349727 | Antidepressants inhibit Nav1.3, Nav1.7, and Nav1.8 neuronal voltage-gated sodium channels more potently than Nav1.2 and Nav1.6 channels expressed in Xenopus oocytes. |
| Q40971013 | Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function |
| Q35028429 | Block by fluoxetine of volume-regulated anion channels |
| Q35636279 | Cellular correlates of enhanced anxiety caused by acute treatment with the selective serotonin reuptake inhibitor fluoxetine in rats |
| Q48198530 | Characterization of human brain pharmacokinetics using a two-compartment model |
| Q45049140 | Combined actions of zinc and fluoxetine on nicotinic acetylcholine receptors. |
| Q60710783 | Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype |
| Q28485344 | Desipramine protects neuronal cell death and induces heme oxygenase-1 expression in Mes23.5 dopaminergic neurons |
| Q48265321 | Detection of fluoxetine in brain, blood, liver and hair of rats using gas chromatography-mass spectrometry |
| Q70946781 | Detection of psychoactive drugs using 19F MR spectroscopy |
| Q44434695 | Differential acute effects of fluoxetine on frontal and auditory cortex networks in vitro |
| Q34559753 | Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement |
| Q38874017 | Direct inhibition of retinoic acid catabolism by fluoxetine |
| Q36953269 | Effect of amitriptyline on tetrodotoxin-resistant Nav1.9 currents in nociceptive trigeminal neurons |
| Q37060285 | Effects of analgesics and antidepressants on TREK-2 and TRESK currents |
| Q51038136 | Effects of diverse psychopharmacological substances on the activity of brain prolyl oligopeptidase. |
| Q45037387 | Effects of norfluoxetine on the action potential and transmembrane ion currents in canine ventricular cardiomyocytes |
| Q28567568 | Effects of norfluoxetine, the major metabolite of fluoxetine, on the cloned neuronal potassium channel Kv3.1 |
| Q36906632 | Essential Contributions of Serotonin Transporter Inhibition to the Acute and Chronic Actions of Fluoxetine and Citalopram in the SERT Met172 Mouse |
| Q73922922 | Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): an in vitro and in vivo study |
| Q48358213 | Evaluation of the binding of the radiolabeled antidepressant drug, 18F-fluoxetine in the rodent brain: an in vitro and in vivo study |
| Q34635770 | Fluorine (19F) MRS and MRI in biomedicine |
| Q28554574 | Fluoxetine Increases the Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines |
| Q89076255 | Fluoxetine Inhibits Canonical Wnt Signaling to Impair Embryoid Body Morphogenesis: Potential Teratogenic Mechanisms of a Commonly Used Antidepressant |
| Q50541378 | Fluoxetine Treatment Induces Seizure Behavior and Premature Death in APPswe/PS1dE9 Mice. |
| Q42822200 | Fluoxetine attenuates the inhibitory effect of glucocorticoid hormones on neurogenesis in vitro via a two-pore domain potassium channel, TREK-1 |
| Q36806023 | Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats |
| Q37597918 | Fluoxetine in progressive multiple sclerosis (FLUOX-PMS): study protocol for a randomized controlled trial. |
| Q35224304 | Fluoxetine regulates neurogenesis in vitro through modulation of GSK-3β/β-catenin signaling |
| Q35741615 | Fluoxetine, an antidepressant, suppresses glioblastoma by evoking AMPAR-mediated calcium-dependent apoptosis |
| Q42682344 | Impact of lipid raft integrity on 5-HT3 receptor function and its modulation by antidepressants. |
| Q48182924 | In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain |
| Q74614946 | Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells |
| Q34099069 | Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants |
| Q35045125 | Inhibition of G protein-activated inwardly rectifying K+ channels by fluoxetine (Prozac). |
| Q43647176 | Inhibition of hippocampal excitability by citalopram |
| Q35041767 | Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine |
| Q24670560 | Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine |
| Q62587219 | Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells |
| Q28293888 | Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor |
| Q58782283 | Lithium and fluoxetine regulate the rate of phosphoinositide synthesis in neurons: a new view of their mechanisms of action in bipolar disorder |
| Q36598509 | MR spectroscopy: its potential role for drug development for the treatment of psychiatric diseases |
| Q30673059 | Magnetic resonance spectroscopy: current and future applications in psychiatric research |
| Q43593948 | Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectroscopy |
| Q40617998 | Mechanism of block by fluoxetine of 5-hydroxytryptamine3 (5-HT3)-mediated currents in NCB-20 neuroblastoma cells |
| Q92861553 | Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis |
| Q48273341 | Monoamine oxidase A inhibition by fluoxetine: an in vitro and in vivo study |
| Q34540452 | Neuroleptic drugs in the human brain: clinical impact of persistence and region-specific distribution |
| Q30841407 | New insights into the intracellular distribution pattern of cationic amphiphilic drugs |
| Q33837768 | Pharmacokinetics of selective serotonin reuptake inhibitors |
| Q40804141 | Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines |
| Q60620847 | Pharmacological characterization of BDNF promoters I, II and IV reveals that serotonin and norepinephrine input is sufficient for transcription activation |
| Q26850811 | Preclinical antiepileptic actions of selective serotonin reuptake inhibitors--implications for clinical trial design |
| Q37378440 | Rationale for the evaluation of fluoxetine in the treatment of enterovirus D68-associated acute flaccid myelitis |
| Q58568748 | Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis |
| Q39218780 | Selective serotonin reuptake inhibitors (SSRIs) inhibit insulin secretion and action in pancreatic β cells |
| Q34677835 | Serotonin and Antidepressant SSRIs Inhibit Rat Neuroendocrine Dopamine Neurons: Parallel Actions in the Lactotrophic Axis. |
| Q35028911 | Serotonin reuptake inhibitor, fluoxetine, dilates isolated skeletal muscle arterioles. Possible role of altered Ca2+ sensitivity |
| Q43691281 | Serotonin reuptake inhibitors fluoxetine and citalopram relax intestinal smooth muscle |
| Q74273507 | Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine |
| Q90018888 | Supratherapeutic Psychotropic Drug Levels in the Emergency Department and Their Association with Delirium Duration: A Preliminary Study |
| Q44506303 | The antidepressant fluoxetine blocks the human small conductance calcium-activated potassium channels SK1, SK2 and SK3. |
| Q48833768 | The antidepressant fluoxetine but not citalopram suppresses synapse formation and synaptic transmission between Lymnaea neurons by perturbing presynaptic and postsynaptic machinery |
| Q48404937 | The antidepressant fluoxetine mobilizes vesicles to the recycling pool of rat hippocampal synapses during high activity |
| Q37624460 | The role of ceramide in major depressive disorder |
| Q33374793 | The role of imaging in proof of concept for CNS drug discovery and development |
| Q38704329 | Therapeutic concentrations of antidepressants inhibit pancreatic beta-cell function via mitochondrial complex inhibition |
| Q33738090 | Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice |
| Q34778793 | Therapeutic potential of fluoxetine in neurological disorders |
| Q33349223 | Time-dependent biphasic modulation of human BDNF by antidepressants in neuroblastoma cells |
| Q90264457 | Toward 19F magnetic resonance thermometry: spin-lattice and spin-spin-relaxation times and temperature dependence of fluorinated drugs at 9.4 T |
| Q44847061 | Tricyclic antidepressant imipramine reduces the insulin secretory rate in islet cells of Wistar albino rats through a calcium antagonistic action |